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Abstract
Objective—To evaluate the impact of transitioning from Medicaid to Medicare Part D drug 
coverage on use of non-cancer treatments among dual enrollees with cancer.
Methods—We leveraged a representative 5% national sample of all fee-for-service dual enrollees 
in the U.S. (2004–2007) to evaluate the impact of the removal of caps on the number of 
reimbursable prescriptions per month (drug caps) under Part D on (1) prevalence and (2) average 
days’ supply dispensed for antidepressants, antihypertensives, and lipid-lowering agents overall 
and by race (white, black).
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Results—The removal of drug caps was associated with increased use of lipid-lowering 
medications (days’ supply: 3.63; 95% CI: 1.57, 5.70). Among blacks in capped states, we 
observed increased use of lipid-lowering therapy (any use: 0.08 percentage points; 95% CI: 0.05, 
0.10; days’ supply: 4.01; 95% CI: 2.92, 5.09), antidepressants (days’ supply: 2.20; 95% CI: 0.61, 
3.78) and increasing trends in antihypertensive use (any use: 0.01 percentage points; 95% 0.004, 
0.01; days supply: 1.83; 95% CI: 1.25, 2.41). The white-black gap in use of lipid-lowering 
medications was immediately reduced (−0.09 percentage points; 95% CI: −0.15, −0.04). We also 
observed a reversal in trends toward widening white-black differences in antihypertensive (level: 
−0.08 percentage points; 95% CI: −0.12, −0.05; trend: −0.01 percentage points; −0.02, −0.01), and 
antidepressant use (−0.004; 95% CI: −0.01, −0.0004).
Conclusions—Our findings suggest that the removal of drug caps under Part D had a modest 
impact on treatment of hypercholesterolemia overall and may have reduced white-black gaps in 
use of lipid-lowering and antidepressant therapies.
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INTRODUCTION
Patients eligible for both Medicare and Medicaid (dual enrollees) are the fastest growing 
segment of the Medicare population.[1–3] Primarily having fee-for-service coverage, these 
vulnerable patients are disproportionately non-white and at higher risk for multi-morbidity. 
In 2006, the Medicare Modernization Act (MMA) shifted prescription drug coverage for 
dual enrollees from Medicaid to privately-administered Medicare Part D plans.[4] Similar 
transitions in drug coverage occur to the present day as newly eligible dual enrollees are 
moved to Part D after a 2-year waiting period.[3]
One key feature of Medicare Part D is that, unlike many state Medicaid programs, Medicare 
Part D prohibits the use of limits, or caps, on the number of medications reimbursed per 
month.[4] Patients with multi-morbidity, who often require multiple medications, are more 
likely to encounter such caps, which may affect their decisions about treatment as they 
anticipate the limit on their coverage.[5,6] For example, to avoid the cap, patients may forgo 
adding a new medication to already complex regimens or forgo medications that prevent 
future adverse events (e.g., antihypertensives) in favor of those perceived to address more 
immediate needs (e.g., cancer treatment).[4,6,7] Prior studies have demonstrated the adverse 
effects that drug caps can have on treatment rates and risk of adverse health outcomes 
among vulnerable, low income patients.[5,8,9]
Dual enrollees with cancer, particularly racial and ethnic minorities, may be 
disproportionately affected by changes in prescription drug coverage due to financial distress 
associated with cancer treatment and high rates of comorbidity requiring ongoing 
medication management.[10–15] Antihypertensive, lipid-lowering and antidepressant 
medications are among the most commonly used prescription medications in this vulnerable 
population and adherence to these treatments is suboptimal.[16–18] Improving access to 
clinically effective medications for dual enrollees with cancer is critical given that dual 
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enrollment and comorbid hypertension, diabetes and depression are independently 
associated with delayed cancer diagnosis, lower quality cancer treatment and adherence, and 
post-operative complications.[19,20]
In addition, dual enrollees with cancer are less likely to receive guideline-consistent cancer 
treatment than non-dually enrolled Medicare beneficiaries.[19] Further, multi-morbidity has 
been identified as a potential determinant of persistent racial disparities in cancer mortality 
more generally, and African Americans, who are disproportionately represented among dual 
enrollees, may be at greater risk for both multi-morbidity and cost-related underuse of 
essential medications.[20–26]
Few studies have explored the impact of the MMA, including transition to Part D, on the 
quality of cancer care and related outcomes for dual enrollees.[27–31] As a consequence, 
little is known about the impact of the transition to Part D, including the removal of drug 
caps, on treatment of common comorbidities among dual enrollees with cancer.
The purpose of this study was to examine the effect of the removal of state-level caps under 
Part D on use of non-cancer drugs among dual enrollees with cancer. We hypothesized that 
the transition to Part D drug coverage would be associated with an increase in access to non-
cancer therapies among dual enrollees living in states where stringent Medicaid drug caps 
were in use. Further, we explored whether response to the policy varied by race, given prior 
evidence of cost related underuse among African Americans with cancer and the importance 
of comorbidity as an underlying determinant of survival in this subgroup.[22–27]
METHODS
Study Design
We used a quasi-experimental design (interrupted time series with comparison series)[32] to 
examine changes in use of lipid-lowering, antihypertensive and antidepressant drugs before 
(2004–2005) and after (2006–2007) the transition of dual enrollees from Medicaid to 
Medicare Part D drug coverage. As described in previous publications,[33–35] we compared 
dual enrollees in states with and without exposure to Medicaid drug caps before the 
transition to Part D. Each subgroup served as its own historical control by providing a 
baseline level and time trend. Since state residency, while not random, should be unrelated to 
changes in use of non-cancer drugs at the time of the transition of dual enrollees to Part D. 
Therefore, this natural experimental design should provide strong evidence of the effects of 
removing drug caps. Lastly, we also examined temporal trends in utilization among a 
subgroup of black and white patients in capped and no-capped states to explore variation in 
use by race.
Our study protocol was reviewed and deemed exempt by the Institutional Review Boards of 
the Kaiser Foundation Research Institute.
Data Sources and Study Population
We used data from a 5% nationally representative sample of linked Medicaid, Medicare, and 
Part D drug claims for dual enrollees for the years 2004 through 2007 provided by the 
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Centers for Medicare and Medicaid Services to identify patients for this analysis.[Figure 1] 
We extracted data for patients with at least one inpatient or two outpatient diagnoses of 
common cancers (breast (174.0–174.9, 175.0, 175.9), colorectal (153.0–153.9, 154.0–154.3, 
154.8), prostate (185), lung (162.0–162.9) or cervical cancer (180, 180.1, 180.8, 180.9, 
182.0)) at any time during baseline (2004–2005) or follow up (2006–2007). We required 
continuous four-year dual enrollment, except in the case of death, with no enrollment in 
Medicare or Medicaid managed care. We excluded 72 enrollees residing in Ohio, Arizona, 
and Louisiana due to data anomalies in those states, such as concurrent changes in coding 
and reporting methods.[36] In addition, we excluded 492 patients who were institutionalized 
for more than three months during the calendar year.
Using publically available data,[37,38] we were able to categorize the remaining states and 
Washington, DC into three Medicaid drug cap policy categories prior to Part D 
implementation: capped (5 or fewer prescriptions of any kind or 3 or fewer prescriptions for 
brand name drugs per month), non-capped, and other state policies that were difficult to 
categorize due to generous cap thresholds and lenient waiver policies. We categorized 196 
patients living in Texas, Oklahoma, Mississippi, and Arkansas as residing in capped states.
We identified a comparison subgroup of 642 dual enrollees who lived in 31 non-capped 
states (full list provided in Figure 1 and Table 1) and the District of Columbia. Eleven states 
(AL, CA, GA, IL, KS, KY, ME, NC, NY, PA, SC) fell into the “other” category and were 
excluded from the analysis to reduce possible misclassification. In addition, we excluded 
Tennessee, which instituted a drug cap policy during the baseline period.[37,38] Our 
analysis focused on the 838 patients living in states in one of the first two categories, and our 
primary exposure of interest was a dichotomous indicator for whether the beneficiary lived 
in a capped versus non-capped state in 2005.
Measures
Drugs of interest included antihypertensive medications, antidepressant agents, and lipid-
lowering drugs and were identified through Medicaid and Part D pharmacy claims using 
National Drug Codes. Our primary outcomes were monthly indicators for (1) prevalence of 
medication use (proportion of patients with medication available during the month based on 
current and prior dispensing) per therapeutic drug class per month and (2) intensity of 
medication use, calculated as the number of days’ supply dispensed per therapeutic drug 
class per month across the entire cohort. Days’ supply is robust to possible changes in the 
quantity allowed per prescription fill between Medicaid and Part D (e.g., 30 vs. 90 day fills).
Data on patient race/ethnicity (white, black, Hispanic, Asian, other), age (categorized as < 
54, 55–64, 65–74, ≥ 75) and sex (male, female) were obtained from Medicaid and Medicare 
administrative files. Race and ethnicity data in the CMS files were derived from the Social 
Security Administration. Sensitivity and specificity are high for blacks (97.4, 98.8). 
Sensitivity is high for whites (99.3%), though specificity is lower at 61.7%. Due to poor 
sensitivity and specificity for other racial/ethnic subgroups, we excluded these groups from 
subgroup analysis.[38] We examined changes in use of study drugs by black and white race 
to assess the differential impacts of the transition to Part D on these groups. Sample sizes for 
other racial/ethnic categories were too small to allow subgroup analyses.
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To characterize the patient populations at baseline, we categorized a subgroup of patients as 
having incident cancer if they had no evidence of cancer in 2004 based on a combination of 
diagnosis codes (ICD 9) and procedure codes (ICD9, revenue, HCPC codes).[40] We used 
enrollment and claims data to identify use of cardiotoxic cancer-directed therapy, diagnosis 
of hypertension, diabetes, or depression, as well as deaths during the study period. 
Cardiotoxic cancer-directed therapies were defined as those associated with increased 
cardiovascular risk (epirubicin, doxorubicin, mitoxantrone, daunorubicin, daunorubicin, 5-
flurouacil, capecitabine, trastuzumab) were identified using a combination of NDC and 
HCPC codes.[41] Comorbid hypertension, diabetes, and depression were identified using 
ICD-9 codes from inpatient and outpatient claims. Last, we identified several additional 
comorbidities associated with cancer or its treatment (haemolytic anemia, 
glomerulonephritis, Grave’s disease, multiple sclerosis, myasthenia gravis, myocarditis, 
polymyositis, dermatomyositis, rheumatic fever and heart disease, rheumatoid arthritis, 
scleroderma, systemic lupus erythematosus, human immunodeficiency virus, hepatitis C, 
Crohn’s disease, Parkinson’s disease, and epilepsy).[42–45] The specific codes used to 
create these measures are available in a footnote on Table 1.
Statistical Analysis
Using interrupted time series (ITS) methods,[32,46] we examined changes in the level and 
slope of the two study outcomes separately for each drug class from before to after the 
transition to Part D, stratifying by capped versus non-capped state status. We excluded 
observations during one month before and three months following the transition to Part D 
(December 2005–March 2006) to allow for temporary state coverage that may have distorted 
outcomes during the transition period.
To estimate policy effects across racial subgroups, we first conducted stratified analyses, 
calculating changes in each of the outcomes before and after policy implementation within 
subgroups defined by race and cap status (e.g., change in the proportion using 
antidepressants among whites in capped states). To directly estimate the impact of the policy 
by race, we then calculated changes over time in the difference in outcomes within capped 
and non-capped states, respectively (e.g., change in the gap between white and black patients 
in use of lipid-lowering agents before and after Part D in capped states). This analysis was 
carried out in the same way for each of the three drug classes.
ITS models are advantageous in that they control for autocorrelation and pre-existing trends 
in medication use. The non-capped states served as a comparison group to help control for 
changes unrelated to Part D transition, such as changes in the economy and drug availability. 
The primary threats to validity in these models are policies that change at the same time as 
the policy change being investigated.[32] Our use of a continuously enrolled cohort rules out 
sudden changes in case mix related to age, sex or comorbidity.
Given that the ITS models required multiple testing (3 therapeutic classes and 2 outcomes 
per class), we estimated that the probability of observing a significant result by chance 
within any subgroup would be equal to 1-(1-0.05)6 or 27%. To reduce the possibility of false 
positives, we applied a Bonferroni correction in which we divided the usual 0.05 level for 
significance by 6, resulting in a p value of 0.008 to judge statistical significance.[47] With 
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this correction, the probability of observing a significant result by chance was reduced to 1-
(1-0.008)6 or 5%. All statistical analyses were conducted using the SAS system (SAS, v.9.0, 
Durham, NC).[48]
Results
Enrollee Characteristics
Baseline patient characteristics are presented in Table 1. Compared to patients in non-capped 
states, dual enrollees in non-capped states were more likely to be white (56% vs. 67%; 
p=0.04) and over the age of 75 (44% vs. 33%; p=0.001). Dual enrollees in capped states 
were less likely to have diagnoses of depression (5% vs. 12%; p=0.004) or of other 
comorbidities associated with cancer or its treatment (8% vs. 13%; p=0.05). We found no 
statistically significant differences in sex, cancer type, incident cancer, use of cardiotoxic 
therapy, or death by cap status.
Baseline Use of Non-Cancer Drugs by State Cap Status
Baseline (January 2005–November 2006) utilization rates for capped and non-capped states 
are presented in Table 2. Compared to dual enrollees in non-capped states, dual enrollees in 
capped states had lower utilization of antidepressants (13% vs. 25%; p<0.01) and lipid-
lowering therapies (21% vs. 31%; p<0.01) at baseline. The mean days’ supply was 
consistently significantly lower (p<0.01) among dual enrollees in capped states for all three 
drug classes (antidepressants: 5.10(1.75) vs. 12.1 (1.19); antihypertensives 36.2 (4.28) vs. 
54.2 (4.09); lipid-lowering agents: 6.75 (1.80) vs. 11.57 (1.11)).
Changes in Use Following the Transition to Part D by State Cap Status
We observed no statistically significant (p<0.008) changes after Part D in the proportion of 
patients with any use of any class of interest in either capped or non-capped states following 
the transition to Part D (Table 3). However, there was a large, marginally significant increase 
in antihypertensive days of supply in capped states [days’ supply: 8.60; 95% CI: 1.22, 16.0] 
that was not present in non-capped states. We also observed a statistically significant 
reduction (difference in days supplied: 3.63; 95%: 1.57, 5.70) in the gap in days’ supply of 
lipid-lowering drugs between dual enrollees in capped states (days’ supply 2.71; 95% CI: 
−0.15, 5.56) relative to those in non-capped states (days’ supply −1.13;95% CI: −2.21, 
−0.05).
Variation in Response by Race
To explore variation in policy response by race, we stratified the models above by white and 
black race and estimated the difference by race within state subgroups (Table 4). The 
transition from Medicaid to Medicare Part D was associated with an immediate increase in 
the prevalence of use of lipid-lowering drugs among blacks in capped states (8 percentage 
points;95% CI: 0.05, 0.10); trend change 0.4 percentage points;95% CI: 0.002, 0.005)) 
(Table 4). Black patients in capped states also experienced an increasing trend in monthly 
prevalence of use of antihypertensive agents (1 percentage point; 95% CI: 0.004, 0.01). 
There were no corresponding changes in prevalence of use for these medications among 
blacks in non-capped states or among whites in either capped or non-capped states.
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Among black patients, the transition to Part D was also associated with increased intensity 
of use of antidepressants (2.20 days supplied; 95% CI: 0.61, 3.78) and of lipid-lowering 
agents (4.01 days supplied; 95% CI: 2.92, 5.09). Blacks in capped states also experienced an 
increasing trend in the intensity of antihypertensive use (1.83 days supplied per month; 1.25, 
2.41). Among whites in capped states, a level increase in intensity of use of 
antihypertensives (12.27 days supplied; 95% CI: 2.11, 22.43) did not reach our more 
conservative threshold for statistical significance. There was also an increasing trend in the 
intensity of antidepressant use among whites in non-capped states (0.16 days per month, 
p=0.006) that was not observed among whites in capped states or among blacks regardless 
of cap status pre-Part D.
In the differenced time series [Table 4, Figure 2], there was an immediate reduction of 9 
percentage points [95%CI: −0.15, −0.04] in the gap between whites and blacks in the 
proportion using lipid-lowering agents in capped states following Part D implementation. In 
addition, a prior trend of increasing white-black differences in antihypertensive use was 
reversed following Part D [−8 percentage points; 95%CI: −0.12, −0.05; trend change: −0.01 
percentage points per month; 95%CI: −0.02, −0.01]. We observed a similar reversal in the 
white-black difference trend for antihypertensive days supplied [trend change: −1.83 days 
supplied per month; 95%CI: −2.81, −0.85]. For antidepressants in capped states, comparable 
reversals in what had previously been upward trends in white-black difference for both 
outcome measures approached, but did not attain, statistical significance [Table 4, Figure 2].
Discussion
In summary, among dual enrollees with cancer, we observed a modest increase in 
antihypertensive days’ supply, as well as reduction in the difference in days’ supply of lipid-
lowering therapy between capped and non-capped states. Part D was not associated with 
overall changes in overall use of antidepressants among dual enrollees with cancer in capped 
relative to non-capped states. These findings are consistent with our prior findings among 
dual enrollees with diabetes showing an increase in use of lipid-lowering agents, but contrast 
with our previous evaluations that showed an increase in use of antidepressants overall.
[33,34]
We also found that the transition from capped state Medicaid programs to Part D was 
associated with evidence of an increase in use of non-cancer drugs among black patients in 
capped states. The largest effect among the three classes we examined was for lipid-lowering 
therapy. Differential effects of the policy by race may reflect differences in how patients 
choose between medications in the presence of drug caps, including higher out of pocket 
costs of lipid-lowering drugs relative to antihypertensives.[37,38] In addition, the ways in 
which patients weigh the benefits and costs of adding medications will likely be influenced 
by how they value medications, which others have reported varies by patient race and 
ethnicity.[49] However, patient decision-making in the face of drug caps is also likely 
influenced by other factors, such as patient-provider communication and the site of care. 
More research is needed to understand the mechanisms responsible for these differences and 
how they might be leveraged to address persistent disparities in treatment.
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This study has some important limitations that merit discussion. First, the analysis, 
particularly the differenced time series by race, is based on small subgroups of patients. 
Therefore, suggesting that more evidence is needed from studies with larger sample sizes to 
examine changes within clinically appropriate subgroups of patients before we can draw 
conclusions about the overall effects of the transition among dual enrollees with cancer and 
comorbid chronic conditions. However, it is important to note that the patients in each of the 
subgroups come from a 5% stratified random sample of all Medicare beneficiaries and, 
therefore, represent a much larger number of patients. Importantly, in ITS models, power is 
also determined by the number of observations before and after the interruption and their 
correlation over time, with the number of subjects contributing primarily to the underlying 
variation in the observed rates. In this case, we had 23 observations before and 22 after the 
intervention.[32,46]
The small sample size limited our ability to explore additional subgroup analyses by cancer 
diagnosis type or among patients with a concurrent comorbidity diagnosis (e.g., breast 
cancer and hypertension). As a result, we cannot evaluate the clinical appropriateness of 
observed changes in utilization, particularly by race. In addition, we were unable to assess 
differences in outcomes by cancer stage and prognosis since these variables are not reported 
reliably in claims data. Both stage and prognosis may impact prescribing and use of other 
non-cancer therapies.
Due to poor sensitivity and specificity of racial/ethnic identification in subgroups other than 
blacks and whites, we excluded other subgroups and may have missed important differences 
by race/ethnicity.[39] For example, previous studies suggest that Latinos, a growing subset 
of the dual enrollee population, may experience considerable barriers to guideline-
concordant cancer and supportive care.[1,2,50–51] Moreover, our findings regarding black 
patients likely reflect the complex myriad social, economic, biological, and cultural factors 
for which race is a proxy.[52] Therefore, race alone is unlikely to serve as a strong or 
reliable predictor of future response as new dual enrollees continue to transition to Part D 
following the 2-year waiting period. Importantly, race may reflect differences in where and 
from whom patients receive care, as well as patient-provider communication about 
treatment, which may be an especially important modifier of racial differences in treatment 
decision-making and response to changes in coverage.[7,53,54]
No true control group exists for this analysis since all dual enrollees made the transition 
from Medicaid to Part D drug coverage. However, our use of ITS models should protect 
against confounding due to gradual changes in case mix within subgroups over time by 
allowing each subgroup to act as its own control. It is important to note that some generic 
versions of branded lipid-lowering (e.g. simvastatin) and antidepressant medications became 
available around the time of the policy change. If the availability of these drugs varied across 
states, such changes could bias our findings. However, the generic substitution rate for all 
state Medicaid programs in 2006 was high at 89% and slightly higher for dual enrollees post 
Part D implementation.[55] In addition, the rate of generic substitution was relatively stable 
across states, ranging from 83% to 91%, suggesting that variation in generic availability is 
not a significant confounder in this analysis.
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Our decision to restrict analyses to continuously-enrolled patients reduces the 
generalizability of our findings although including patients who died during the year may 
have reduced the impact of this decision. Since this is an observational study, we could not 
control for any confounders that occurred simultaneously with the policy, such as state 
outreach or educational efforts that carried on well after policy implementation.
This study also has a number of strengths. The quasi-experimental design is one of the 
strongest observation study designs for evaluating policy effects. In addition, the use of a 
large, representative sample of dual enrollees with cancer increases the generalizability of 
study findings.
Conclusion
Dual enrollees with cancer are a highly vulnerable subgroup of the Medicare population.
[1,2,51] Our findings suggest that the removal of caps due to the transition of dual enrollees 
from Medicaid to Medicare Part D may have had a modest overall impact on access to non-
cancer therapies among patients with cancer. However, we found some evidence of racial 
differences in response, indicating that blacks may have benefitted more than whites from 
the transition. Given substantial growth in the dual enrollee population as a result of 
Medicaid expansions under the Affordable Care Act [56] and the continued use of strict drug 
caps as a cost containment tool within state Medicaid programs,[37,38] understanding the 
reasons behind differential response to this transition is critical to assessing whether the 
ongoing transition of dual enrollees to Part D will result in improved access to care. 
Specifically, exploring the mechanisms by which this and similar changes in coverage affect 
access to non-cancer therapies can inform the development of strategies to maximize the 
potential for such policies to ensure access to clinically essential services, especially among 
groups of patients that experience disparities in access due to restricted coverage.
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Figure 1. 
Cohort Selection Process for Analysis of Dual Enrollees with Cancer
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Figure 2. 
Estimated difference (white-black) in the proportion of patients with any use by drug class 
among dual enrollees with cancer in capped states (2004–2007)*
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Table 1
Baseline (2005) Characteristics of Dual Enrollees with Cancer in States with and without Restrictive Drug 
Caps
All
N=838
Cap States*
N=196
Non Cap States**
N=642
p-value
State with Drug Caps
 No 642 (77%) 0 642 (100%)
 Yes 196 (23%) 196 (100%) 0
Race/Ethnicity 0.040
 White 542 (65%) 110 (56%) 432 (67%)
 Black 177 (21%) 55 (28%) 122 (19%)
 Asian 37 (4%) <10 (4%) 29 (4%)
 Hispanic 60 (7%) 16 (8%) 44 (7%)
 Other 22 (3%) <10 (4%) 15 (2%)
Gender 0.780
 Male 164 (20%) 37 (19%) 127 (20%)
 Female 674 (80%) 159 (81%) 515 (80%)
Age 0.001
 ≤54 113 (13%) 15 (8%) 98 (15%)
 55–64 117 (14%) 18 (9%) 99 (15%)
 65–74 309 (37%) 77 (39%) 232 (36%)
 ≥75 299 (36%) 86 (44%) 213 (33%)
New Cancer Diagnosis
 No 338 (40%) 72 (37%) 266 (41%) 0.241
 Breast 168 (20%) 37 (19%) 131 (20%) 0.640
 Prostate 18 (2%) -- (1%) 15 (2%) 0.496
 Colorectal 164 (20%) 43 (22%) 121 (19%) 0.340
 Cervical 94 (11%) 27 (14%) 67 (10%) 0.195
 Lung 56 (7%) 14 (7%) 42 (6%) 0.768
Cardiotoxic Cancer Treatment 0.831
 No 710 (85%) 167 (85%) 543 (85%)
 Yes 128 (15%) 29 (15%) 99 (15%)
Hypertension Diagnosis† 542 (65%) 136 (69%) 406 (63%) 0.115
Diabetes Diagnosis† 277 (33%) 60 (31%) 217 (24%) 0.406
Depression Diagnosis† 89 (11%) 10 (5%) 79 (12%) 0.004
Other Comorbid Conditions† 102 (12%) 16 (8%) 86 (13%) 0.050
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All
N=838
Cap States*
N=196
Non Cap States**
N=642
p-value
Died 127 (15%) 29 (15%) 98 (15%) 0.645
*
TX, OK, MS, AR
**AK, CO, CT, DE, FL, HI, IA, ID, IN, MA, MD, MN, MO, MT, ND, NE, NH, NM, NV, OR, RI, SD, UT, VA, VT, WA, WI, NV, WY, 
Washington, DC
†
Evidence of the following diagnoses at any time between 2004 and 2007. Hypertension: ICD9-CM=401,401.0, 401.1, 401.9, 402, 403, 403.0, 
403.1, 404, 405, 405.0, 405.01, 405.11; Diabetes: ICD9-CM=250.XX; Depression: ICD9-CM=296.20–296.26; 296.30–296.36; 296.89; 298.0, 
300.4, 301.12, 309, 309.0, 309.1, 309.28, 311; Other comorbid conditions: haemolytic anemia: 283.0–283.2; glomerulonephritis: 580.0–583.9; 
Graves disease: 242.00–242.91; multiple sclerosis: 340; myasthenia gravis: 358.0; myocarditis: 130.3, 422.0, 422.0, 429.0; polymyositis/
dermatomyositis: 710.3, 710.4; rheumatic fever and heart disease: 390–398.9; rheumatoid arthritis: 714.0–714.2; diffuse diseases of connective 
tissue (includes systemic lupus, scleroderma): 710.0–710.5, 710.8, 710.9; Human Immunodeficiency Virus: 042; hepatitis C: 070.54; Crohn’s 
disease: 555.0, 555.1, 555.9; Parkinson’s disease: 332.0, 332.1; and epilepsy: 345.00, 345.10, 345.11, 345.2, 345.3, 345.40, 345.41, 345.50, 345.51, 
345.70, 345.71, 345.80, 345.81,345.90, 345.91
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